{
    "clinical_study": {
        "@rank": "110877", 
        "arm_group": [
            {
                "arm_group_label": "Epstein + (group I)", 
                "arm_group_type": "Active Comparator", 
                "description": "Epstein + (Group I) PSA <10 ng/ml Gleason 3+3=6 Number of positive biopsies <3/12\n% of tumor biopsy invasion <50% Tumor volume <0.5cm3 c-rTNM T1-T2a N0 M0"
            }, 
            {
                "arm_group_label": "Epstein - (group II)", 
                "arm_group_type": "Experimental", 
                "description": "Epstein - (Group II) PSA <15 ng/ml Gleason score max 3+4 Number of positive biopsies <5/12\n% of tumor biopsy invasion <50% Tumor volume <1cm3 T1-T2c N0 M0"
            }
        ], 
        "brief_summary": {
            "textblock": "Active Surveillance manages selected men with prostate cancer expectantly with curative\n      intent. This means men are carefully selected and subsequently actively observed in order to\n      have the possibility to offer them curative treatment once the tumor seems to progress.\n\n      The goal of this study is to validate the treatment option Active Surveillance in men with\n      localized, well differentiated prostate cancer, in order to limit the amount of\n      overtreatment. A number of key points will be studied, such as the pathological findings in\n      radical prostatectomy specimens, and the effect of expectancy on the quality of life."
        }, 
        "brief_title": "Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Adenocarcinoma of the Prostate", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objectives:\n\n      Primary\n\n      - To evaluate the equivalence of the time on active surveillance before an active treatment\n      between group Epstein + and the expanded active surveillance group (Epstein -)\n\n      Secondary\n\n        -  To evaluate the role of diffusion-weighted MRI (DW-MRI) in the initial diagnosis and\n           the follow-up of patients under active surveillance\n\n        -  To evaluate the role of BCAR-1 to predict the clinical outcome of localized prostate\n           cancer\n\n        -  To evaluate patients quality of life\n\n        -  To evaluate the proportion of patients who discontinued active surveillance\n\n        -  To evaluate the mortality at 10, 15 and 20 years from the inclusion in the study\n\n        -  To evaluate the time to metastatic disease\n\n        -  To evaluate the time to radical treatment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Localized adenocarcinoma of the prostate with a Gleason score of 3+3 (group I\n             patients) or 3+4 (group II patients)\n\n          -  Percentage of tumor biopsy invasion <50% with a number of positive tumor biopsies <3\n             (group I patients) or \u2264 4 (group II patients)\n\n          -  TNM stage T1-2a N0 M0 (group I patients); TNM stage T1-2c N0 M0 (group II patients)\n\n          -  PSA level at diagnosis < 10 ng/ml for group I patients; < 15 ng/ml for group II\n             patients\n\n          -  Tumor volume <0.5 ml (group I patients); <1 ml (group II patients)\n\n          -  Absence of extra-capsular extension\n\n          -  Life expectancy > 10 years\n\n          -  Signed informed consent\n\n          -  Patient has elected active surveillance as preferred management plan for the prostate\n             cancer\n\n        Exclusion Criteria:\n\n        - Previous treatment for prostate cancer (including hormonal therapy, radiation therapy,\n        surgery or chemotherapy)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795365", 
            "org_study_id": "CHUV Active surveillance"
        }, 
        "intervention": {
            "arm_group_label": [
                "Epstein + (group I)", 
                "Epstein - (group II)"
            ], 
            "intervention_name": "Active surveillance", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2013", 
        "location": {
            "contact": {
                "email": "patrice.jichlinski@chuv.ch", 
                "last_name": "Patrice Jichlinski, MD", 
                "phone": "41-21-314-2980"
            }, 
            "facility": {
                "address": {
                    "city": "Lausanne", 
                    "country": "Switzerland"
                }, 
                "name": "Centre Hospitalier Universitaire Vaudois (CHUV)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Centre Hospitalier Universitaire Vaudois", 
            "last_name": "Patrice Jichlinski, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients on active surveillance in group Epstein + and Epstein -", 
            "safety_issue": "Yes", 
            "time_frame": "6 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795365"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre Hospitalier Universitaire Vaudois", 
            "investigator_full_name": "Prof. Patrice Jichlinski", 
            "investigator_title": "Chief of Urology Department, University of Lausanne Hospitals", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor volume increased, extra-capsular extension or presence of adenopathy assessed on DW-MRI", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12, 24, 48 months and every two years."
            }, 
            {
                "measure": "BCAR-1 test on biopsies", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12, 24 months and every 4 years"
            }, 
            {
                "description": "IPSS score/IIEF-5 score( QLQ-C30 + PR25)", 
                "measure": "Quality of life assessment", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months for 6 years"
            }, 
            {
                "measure": "Percentage of patients who discontinued active surveillance by categories (patient's will, clinical or histological criterion)", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months for 6 years"
            }, 
            {
                "measure": "Percentage of deceased patients 10, 15 and 20 years from the inclusion in the study in both groups", 
                "safety_issue": "No", 
                "time_frame": "10, 15, 20 years"
            }, 
            {
                "measure": "Percentage of patients who progressed to a metastatic stage at different time points in both groups", 
                "safety_issue": "Yes", 
                "time_frame": "Every year for 6 years"
            }, 
            {
                "measure": "Percentage of patients who underwent radical treatment at different time points in both groups", 
                "safety_issue": "Yes", 
                "time_frame": "Every 6 months for 6 years"
            }
        ], 
        "source": "Centre Hospitalier Universitaire Vaudois", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Vaudois", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}